|
Home Book Browser | |||
|
|
|||
|
MedicalScienceBooks.com Medical Book Review: The debate on optimal treatment strategies for patients with lipid disorders, although ongoing for many years, has been particularly energized over the past decade in response to increased pharmaceutical research efforts. Evidence-based Management of Lipid Disorders is one of several publications recently written which take a global view of clinical trial data accumulated from studies on a number of risk factors associated with blood lipids. Therefore, much of the information included in this book can readily be found in other resources. Does this book offer any unique insights or fresh perspectives on the subject matter? The reader will have to answer these questions for themselves, but most likely will find value in this book. The busy clinician is called upon to make difficult treatment decisions based on blood lipid profiles. Many decisions need to be made without clear guidelines, particularly those dealing with treatment initiation in younger patients who may not have a cluster of cardiovascular risk factors. This text places more emphasis on these issues than typically found in the literature. There is also a focus on information regarding "hot topics" including the effects of plant sterols and combination therapies on blood lipids. The authors use their clinical experience to weigh in, where appropriate, on topics which lack a solid research base and conservatively put clinical trial results in perspective. For cardiologists and general practitioners looking for a concise resource covering the nuances of treating lipid disorders, Evidence-based Management of Lipid Disorders is a great option.
Description:
Practicing evidence-based
medicine necessarily depends on
the clinician having access to
the best evidence available, but
in a fast-moving field, keeping
up to date with the latest
developments is a challenging
prospect. In this new volume,
leading experts focus on the
most important clinical issues
associated with the management
of Lipid Disorders, evaluating
and interpreting the evidence
available to provide the reader
with a reliable summary of our
current knowledge.
Topics covered include therapeutic strategies for managing hereditary lipid disorders, including familial hypercholesterolaemia, both in adults and children, and familial combined hypercholesterolaemia.The authors also evaluate the evidence for a link between inflammatory disease and cardiovascular risk; the metabolic syndrome and the interconnections between dyslipidaemias and diabetes. They also look at therapeutic challenges such as the management of patients who are statin resistant, and the control of lipid levels in those suffering renal insufficiency. Tables highlight important data, evidence from trial results and expert reports, and each section concludes with a series of Key Points that present a summary of evidence-based recommendations for best practice, graded according to the quality of that evidence. The book provides the busy clinician with a unique analysis of the data supporting current therapies and will help the reader formulate effective strategies for treating their own patients. Table of Contents: Foreword Chapter 1. How much evidence is enough? Chapter 2. A brief review of lipoprotein metabolism Chapter 3. Epidemiological aspects of lipid and lipoprotein levels in relation to cardiovascular diseases Chapter 4. Are LDL cholesterol-lowering functional food ingredients successful in the long term? Chapter 5. Evidence-based treatment of primary hypo- and hypercholesterolemic dosorders Chapter 6. Does raising HDL protect against atherosclerosis? Chapter 7. How do we diagnose hypertriglyceridemia in clinical practice and what are the consequences for treatment? Chapter 8. The optimal treatment of patients with familial combined hyperlipidemia Chapter 9. How to manage lipid and lipoprotein disorders in children Chapter 10. Contribution of the atherogenic dyslipidemic phenotype to the increased cardiovascular disease risk of the metabolic syndrome and diabetes mellitus Chapter 11. What are the consequences of renal insufficiency or the nephrotic syndrome for lipid levels? Chapter 12. The link between chronic inflammatory diseases and cardiovascular risk Chapter 13. What is the evidence for a physiological and pathogenic role of lipoprotein (a)? Chapter 14. Sitosterolemia; xenophobia for the body Chapter 15. How can we deal with inborn errors in cholesterol and bile acid biosynthesis? Chapter 16. Differential diagnosis of patients with xanthomas and xanthelasmata Chapter 17. When should we fear statin interactions? Chapter 18. What are the considerations in patients who are statin 'intolerant'? |
||||
|
Copyright 2010 ©
BioWeb Concepts. All rights
reserved |
||||
